Stay updated with breaking news from Cholesterol Efflux. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical...
Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic…
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease....
This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and progression of chronic kidney disease .ZyVersa’s...